


**Supplementary Tables and Figures**

**Supp. Table 1. Mean (STD) Plasma Bortezomib Concentration Following Intravenous and Subcutaneous Injection**


Cycle	Day	Hour	Intravenous(IV)			Subcutaneous(SC)			P value (Wilcoxon)
			N	Mean	STD	N	Mean	STD	
1	1	Pre dose	10	BQL	.	10	BQL	.	
	1	5min	10	98.84	39.27	10	13	15.79	0.0002
	1	30min	10	8.73	5.59	10	20.5	10.91	0.0082
	1	5hours	10	1.82	1.31	9	1.96	0.56	0.1025
	8	Pre dose	10	0.44	0.15	10	0.33	0.09	0.1988
	15	Pre dose	8	0.66	0.22	10	0.49	0.12	0.0756
	22	Pre dose	7	0.83	0.34	9	0.66	0.18	0.5604
	22	5min	7	114.3	76.6	9	10.29	13.24	0.0012
	22	30min	7	14.9	4.3	9	21.69	10.1	0.189
	22	5hours	7	2.85	1.05	9	4.16	2.07	0.2664
2	1	Pre dose	9	0.53	0.15	9	0.49	0.14	0.6587

min - minutes


**Supp. Figure 1. Boxplot of Bortezomib Concentration Levels for Each Time Point**




### Day 15 pre-dose




### Day 22 pre-dose




### Day 22 5 minutes




### Day 22 30 minutes



### Day 22 5 hours



### Day 36 pre-dose (cycle 2)



**Supp. Table 2. Quality of Life (QOL): EORTC QLQ-C30 and MY20**

	N*	Baseline		EOT		P-value
		Mean (SD)	Median	Mean (SD)	Median	
<b>Global health status / QoL</b>						
Global health status/QoL	30	63.6 (27.3)	66.7	69.4 (20.8)	75.0	0.6471
<b>Functional scales</b>						
Physical functioning	30	68.4 (30.9)	83.3	79.6 (18.4)	86.7	0.0125
Role functioning	30	67.8 (36.3)	75.0	76.7 (29.9)	91.7	0.2110
Emotional functioning	30	78.1 (20.8)	83.3	79.7 (27.3)	87.5	0.5326
Cognitive functioning	30	78.3 (28.1)	83.3	82.8 (22.9)	83.3	0.7504
Social functioning	30	75.0 (29.9)	100.0	79.4 (25.4)	83.3	0.3297
Body image	28	86.9 (29.2)	100.0	85.7 (23.0)	100.0	0.7422
Future perspective	28	62.7 (22.3)	66.7	72.2 (21.9)	66.7	0.0227
<b>Symptom scales / items</b>						
Fatigue	30	35.6 (27.0)	33.3	28.7 (21.7)	27.8	0.1913
Nausea and vomiting	30	5.0 (11.7)	0	5.0 (16.5)	0	0.7188
Pain	30	34.4 (37.1)	25.0	21.1 (23.9)	16.7	0.0616
Dyspnea	30	23.3 (34.1)	0	12.2 (22.3)	0	0.1016
Insomnia	29	26.4 (32.6)	33.3	23.0 (29.7)	0	0.7126
Appetite loss	30	18.9 (29.9)	0	15.6 (24.3)	0	0.2832
Constipation	30	25.6 (33.5)	0	13.3 (20.7)	0	0.1042
Diarrhea	30	10.0 (17.8)	0	20.0 (29.8)	0	0.1851
Financial difficulties	30	16.7 (24.4)	0	15.6 (24.3)	0	0.4795
Disease symptoms	29	30.9 (27.4)	22.2	16.5 (13.9)	11.1	0.0009
Side effects of treatment	29	15.6 (13.3)	11.1	12.8 (12.3)	7.4	0.3492

\* only patients having both baseline and EOT scores were included.